Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer

Jin-Young Jang,Youngmin Han,Hongeun Lee,Sun-Whe Kim,Woo Il Kwon,Kyung-Hun Lee,Do-Youn Oh,Eui Kyu Chie,Jeong-Min Lee,Jin Seok Heo,Joon-Oh Park,Do-Hoon Lim,Seong Hyun Kim,Sang-Jae Park,Woojin Lee,Young-Hwan Koh,Joon Seong Park,Dong Sup Yoon,Ik Jae Lee,Seong Ho Choi

Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer

2018

Objective:This study was performed to determine whether neoadjuvant treatment increases survival in patients with BRPC.Summary Background Data:Despite many promising retrospective data on the effect of neoadjuvant treatment for borderline resectable pancreatic cancer (BRPC), no high-level evidence e

Keywords:

Gemcitabine
Surgery
Resectable Pancreatic Cancer
Medicine
Pancreatic cancer
in patient
open label
neoadjuvant treatment
retrospective data
borderline resectable
background data

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

246

Citations